Thermo Fisher Scientific Opens $75M Cryo-EM Drug Discovery Center in South San Francisco

Thermo Fisher Scientific (TMO) has officially opened its new Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center in South San Francisco, marking a pivotal expansion of its life sciences R&D capabilities. The center, located in a key biotech hub, houses 12 high-resolution cryo-EM instruments, including the latest generation of Thermo Fisher’s Titan Krios systems, enabling atomic-level visualization of proteins and drug targets. The facility is designed to support over 100 collaborative research projects annually, with a focus on oncology, neurodegeneration, and rare diseases. The $75 million investment underscores TMO’s strategic commitment to advancing structural biology as a cornerstone of precision medicine. By enabling near-atomic resolution imaging of biomolecular complexes in their natural states, the center reduces the time required to identify viable drug candidates from years to months. This capability positions TMO as a key enabler for pharmaceutical and biotech firms, including those in its partner network such as Vertex Pharmaceuticals (VRTX), which has already initiated pilot studies using the facility’s resources. The new center is expected to support the development of targeted therapies, particularly for challenging protein targets previously inaccessible to traditional drug discovery methods. With the global cryo-EM market projected to grow at a compound annual rate of 18.5% through 2030, TMO’s move strengthens its leadership in the life sciences tools segment. The facility also aligns with broader industry trends in biopharma innovation, boosting confidence in the sector’s long-term trajectory—reflected in the performance of biotech ETFs like IBB and healthcare-focused ETFs such as XLV. The opening of the center is anticipated to drive increased demand for high-end instrumentation and specialized technical services, bolstering TMO’s revenue streams and expanding its footprint in the global R&D ecosystem. The initiative also strengthens South San Francisco’s status as a biotech innovation corridor, attracting talent and partnerships across academia and industry.